Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupDermatologic OncologyT-Cell and NK-Cell NeoplasmsDiseaseNHL, T-Cell Type, Cutaneous, UnspecifiedNHL, T-Cell Type, Cutaneous Primary, CD30-PositiveNHL, T-Cell Type, Mycosis FungoidesNHL, T-Cell Type, Sézary SyndromeSubgroupCD30+ICD10C84.0C84.1C84.8C86.6MeSHMycosis FungoidesSezary SyndromeSequenceMAVORIC: MOGA1, CTCL, C1 (PID1397) -|- C2-12 (PID1398)Antineoplastic therapySubstanceBrentuximab vedotinCladribineDenileukin DiftitoxDoxorubicin pegylated liposomalGemcitabineLenalidomideMogamulizumabPembrolizumabPentostatinTemozolomideSubstanceBrentuximab vedotinCladribineDenileukin DiftitoxDoxorubicin pegylated liposomalGemcitabineLenalidomideMogamulizumabPembrolizumabPentostatinTemozolomideSubstanceBrentuximab vedotinCladribineDenileukin DiftitoxDoxorubicin pegylated liposomalGemcitabineLenalidomideMogamulizumabPembrolizumabPentostatinTemozolomideSubstanceBrentuximab vedotinCladribineDenileukin DiftitoxDoxorubicin pegylated liposomalGemcitabineLenalidomideMogamulizumabPembrolizumabPentostatinTemozolomideAnzahl Substanzen1 RadiotherapySupportive therapySubstanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPyridoxineSubstanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPyridoxineSubstanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPyridoxineSubstanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPyridoxineAnzahl Substanzen12347Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationRelapse therapySecond lineseveral possibleThird line Therapy phaseTherapy intentiondisease controlpalliativeRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlArthalgiaAstheniaCapillary Leak SyndromeColitisDiarrheaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHeadacheHypertensionHypoalbuminemiaIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaMucositisNauseaNeuropathyNeutropeniaPancreatitisPneumoniaPneumonitisPruritusPyrexiaSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorDuvic MFoss FMKhodadoust MSKim YHPrince HMQuereux GQuerfeld CQuerfeld C Saven ATsimberidou AMDiseasefortgeschrittenes, kutanes T-Zell-LymphomKutanes T-Zell-Lymphom (inkl. Mycosis fungoides oder Sézary-Syndrom)kutanes T-Zell-Lymphom, CD30+, mindestens eine Vortherapie, ECOG 0-2Kutanes T-Zell-Lymphom, Stadium IB-IVB, mindestens eine Vortherapie, ECOG 0-2Refraktäres oder rezidivierendes kutanes T-Zell-Lymphom (Mycosis fungoides oder Sézary-Syndrom), Stadium IA bis IVA, ECOG 0-1Refraktäres oder rezidivierendes kutanes T-Zell-Lymphom (Mycosis fungoides oder Sézary-Syndrom), Stadium IB - IV, ECOG 0-1Refraktäres oder rezidivierendes kutanes T-Zell-Lymphom (Mycosis fungoides oder Sézary-Syndrom), Stadium IB bis IVA, ECOG 0-1Refraktäres oder rezidivierendes kutanes T-Zell-Lymphom (Mycosis fungoides oder Sézary-Syndrom), Stadium IIB - IV, ECOG 0-1refraktäres oder rezidivierendes kutanes T-Zell-Lymphom, 2 oder mehr Vorbehandlungen, ECOG 0-2refraktäres oder rezidivierendes kutanes T-Zell-Lymphom, eine oder mehr Vorbehandlungen, ECOG 0-1OriginDepartment of Dermatology, Northwestern University, Chicago, Illinois, USADepartment of Dermatology, The University of Texas M. D. Anderson Cancer Center, HoustonDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TexasDepartment of Medicine/Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, NYDepartments of Dermatology, Centre Hospitalier Universitaire, Nantes, FranceDivision of Cancer Medicine, Peter MacCallum Cancer Centre, The University of Melbourne, ALCANZADivision of Hematology and Oncology, Scripps Clinic, La Jolla, CAStanford University, Stanford, CAStanford University, Stanford, CA, USA, MAVORICYale University School of Medicine, New Haven, CTProtocols in Revision 11 protocols foundBrentuximab Vedotin 1.8, cutaneous T-cell lymphoma (PID1389 V1.0)Cladribine 0.05, cutaneous T-cell Lymphoma (PID3053 V1.0)Denileukin Diftitox 9, cutaneous T-cell Lymphoma (PID3046 V1.0)Gemcitabine 1000, cutaneous T-cell lymphoma (PID1388 V1.0)Lenalidomide 25, cutaneous T-cell lymphoma (PID3045 V1.0)Mogamulizumab 1, cutaneous T-cell lymphoma, cycle 1 (PID1397 V1.0)Mogamulizumab 1, cutaneous T-cell lymphoma, cycle 2-12 (PID1398 V1.0)Pegylated Doxorubicin Liposomal 40, cutaneous T-cell lymphoma (PID1387 V1.0)Pembrolizumab 200, cutaneous T-cell Lymphoma (PID3049 V1.0)Pentostatin 5, cutaneous T-cell Lymphoma (PID3048 V1.0)Temozolomide 200, cutaneous T-cell lymphoma (PID3047 V1.0)
